Samuli Eldfors

14PUBLICATIONS
65CO-AUTHORS
Medical infection agents (incl. prions)Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 06, 2026
Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

|Aug 17, 2026
Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification.

|May 25, 2026
Liquid Biopsy of HPV Cell-Free DNA Enables Blood-Based Early Detection and Molecular Stratification of HPV-Associated Cancer and Precancer Stages.

|Nov 24, 2025
Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

Samuli Eldfors, Sumit Rai, Vineet Sharma

|Jan 10, 2024
Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia.

Samuli Eldfors, Joseph Saad, Nemo Ikonen

|Dec 12, 2022
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.

Heikki Kuusanmäki, Olli Dufva, Markus Vähä-Koskela

Pageof 3

Frequent Collaborators

4 joint publications

O Kallioniemi

4 joint publications

Kimmo Porkka

4 joint publications

Satu Mustjoki

3 joint publications

Caroline A Heckman